前列腺癌中的5α还原酶抑制剂：从临床试验到临床实践 - Suppr

Suppr

超能文献

5-alpha Reductase inhibitors in prostate cancer: from clinical trials to clinical practice.

作者信息

Ehdaie Behfar, Touijer Karim A

出版信息

Eur Urol. 2013 May;63(5):788-9; discussion 790-1. doi: 10.1016/j.eururo.2012.12.035. Epub 2013 Jan 2.

DOI:10.1016/j.eururo.2012.12.035

PMID:23305882

Abstract

摘要

相似文献

5-alpha Reductase inhibitors in prostate cancer: from clinical trials to clinical practice.

Eur Urol. 2013 May;63(5):788-9; discussion 790-1. doi: 10.1016/j.eururo.2012.12.035. Epub 2013 Jan 2.

Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).

Eur Urol. 2013 May;63(5):779-87. doi: 10.1016/j.eururo.2012.11.006. Epub 2012 Nov 12.

High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.

Prostate. 2013 Jun;73(9):923-31. doi: 10.1002/pros.22638. Epub 2013 Jan 17.

Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9.

[Considerations about the value of prostate specific antigen in patients treated with 5-α reductase].

Semergen. 2013 Mar;39(2):118. doi: 10.1016/j.semerg.2012.07.003. Epub 2012 Sep 13.

Ask the doctor. I take Avodart for my enlarged prostate. But I heard that Avodart increases prostate cancer risk. Is that true? Should I quit taking Avodart?

Harv Health Lett. 2012 Jan;37(3):8.

5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk?

Curr Urol Rep. 2013 Jun;14(3):223-6. doi: 10.1007/s11934-013-0324-y.

The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.

Urology. 2005 Jan;65(1):76-82. doi: 10.1016/j.urology.2004.08.042.

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

Eur Urol. 2012 Nov;62(5):757-64. doi: 10.1016/j.eururo.2012.05.025. Epub 2012 May 18.

Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

BJU Int. 2012 Apr;109(8):1162-9. doi: 10.1111/j.1464-410X.2011.10373.x. Epub 2011 Jun 23.

引用本文的文献

Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.

J Clin Aesthet Dermatol. 2016 Jul;9(7):56-62. Epub 2016 Jul 1.

Prostate Cancer Prevention: Concepts and Clinical Trials.

Curr Urol Rep. 2016 Apr;17(4):35. doi: 10.1007/s11934-016-0587-1.

Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Rev Endocr Metab Disord. 2015 Sep;16(3):177-98. doi: 10.1007/s11154-015-9319-y.

The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression.

Korean J Urol. 2014 Jun;55(6):367-79. doi: 10.4111/kju.2014.55.6.367. Epub 2014 Jun 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验